Lpath, Inc. Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com

NEW YORK, June 6, 2011 /PRNewswire/ -- Lpath, Inc. (OTC: LPTN), the industry leader in lipidomics-based therapeutics, today announced that their June 2nd RetailInvestorConferences.com presentation is available for on-demand viewing.

To access, follow this link: www.retailinvestorconferences.com and click on: “Register/Watch Event Now!”

The archived replay of the presentation will be available for 90 days. Investors may download shareholder materials from the “virtual booth” for the next three weeks.

About Lpath

San Diego-based Lpath, a therapeutic antibody company, is the category leader in lipidomics-based therapeutics, an emerging field of medicine that targets bioactive signaling lipids for treating a wide range of human disease. Lpath’s ImmuneY2 drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company has developed three drug candidates, two of which -- iSONEP for wet AMD and ASONEP for cancer -- have completed Phase 1 clinical trials. Lpath entered into an agreement with Pfizer in 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP. For more information, visit www.Lpath.com.

About RetailInvestorConferences.com:

RetailInvestorConferences.com, created by BetterInvesting (NAIC), PR Newswire and MUNCmedia, is the first monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire’s leading-edge online conferencing and investor communications capabilities with BetterInvesting’s extensive retail investor audience network and MUNCmedia’s sophisticated retail investor targeting.

SOURCE Lpath, Inc.

MORE ON THIS TOPIC